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Whey, a liquid by-product, is widely accepted to contain many valuable constituents. These include especially proteins that possess
regard to promotion of health, as well as prevention of diseases andimportant nutritional and biological properties – particularly withhealth conditions. Antimicrobial and antiviral actions, immune system stimulation, anticarcinogenic activity and other metabolic fea-WHOLE
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Fig. 1. Schematic diagram of acid- and rennet-mediated cheese making.
Table 1
Protein proﬁle of whey and primary structure basic properties
Protein Concentration
a,d
Molecular weight
b,c
Number of
have indeed been associated with such whey proteins, as a-lactalbumin, b-lactoglobulin, lactoferrin, lactoperoxidase, and bovine
albumin. The most important advances reported to date pertaining to biological properties of whey proteins are reviewed in this
unication.Drinking milk is a practice that dates back to the domes-
tication of animals in prehistoric times, and has taken
advantage of the extensive nutritional value of that natural
product – not only to the young born, but also to the child,
the adult and the elderly. However, one major part of milk
– whey, has traditionally not been paid as much attention
as happened with source milk, probably because it is a
by-product of cheese making, viewed for a long time as
of little value (besides additive to animal feed). Interest-
ingly, Hippocrates already applauded the health properties
of whey in Ancient Greece; and during the Middle Age,
whey was considered not only as a medicine, but also even
as an aphrodisiac and a skin balm: it was in fact a regular
component of salves and potions to soothe burns, to
inspire vitality and to cure various illnesses (Kosikowski,
1982). Recent decades have witnessed an increased interest
in whey protein products, owing to their nutritional role,
and more and more to their active role upon human health.
A multitude of bibliographic material covering that topic
has accordingly been published; this review will focus on
     Introduction  ost recent research advances pertaining to the biolog- (g/l) (kDa) amino acids
residuesb
b-Lactoglobulin 1.3 18,277 162
a-Lactalbumin 1.2 14,175 123
Bovine serum albumin 0.4 66,267 582
Immunoglobulins
(A, M and C)
0.7 25,000 (light
chain) + 50,000–
70,000 (heavy
chain)
–
Lactoferrin 0.1 80,000 700
Lactoperoxidase 0.03 70,000 612
Glycomacropetide 1.2 6700 64
a de Wit (1998).
b Eigel et al. (1984).
c Brew et al. (1970).
d Korhonen (1995).ical properties of whey proteins.
Milk possesses a protein system constituted by two
major families of proteins: caseins (insoluble) and whey
proteins (soluble). Caseins account for 80% (w/w) of the
whole protein inventory, and can easily be recovered from
skim milk via isoelectric precipitation (by addition of, or
in situ production of acid) or rennet-driven coagulation –
both of which release whey as by-product (Fig. 1). Whey
proteins are globular molecules with a substantial content
of a-helix motifs, in which the acidic/basic and hydropho-
bic/hydrophilic amino acids are distributed in a fairly bal-
anced way along their polypeptide chains (Evans, 1982).
The whey protein proﬁle, including general chemical
and physiochemical properties, is depicted in Table 1.
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systemproteins include b-lactoglobulin (b-LG, for short),
albumin (a-LA), immunoglobulins (IG), bovineserum albumin (BSA), bovine lactoferrin (BLF) and lac-
toperoxidase (LP), together with other minor compo-
nents. Their main biological activities are summarized in
Table 2.
Table 2
Biological functions of whey proteins
Protein Biological function References
Whole whey proteins Prevention of cancer
 Breast and intestinal cancer
 Chemically induced cancer
Gill and Cross (2000)
Badger et al. (2001), MacIntosh et al. (1995)
Hakkak et al. (2000), Rowlands et al. (2001)
Increment of gluthatione levels
 Increase of tumour cell vulnerability
 Treatment of HIV patients
Parodi (1998)
Micke et al. (2001), Micke et al. (2002)
Antimicrobial activities Clare et al. (2003)
Increment of satiety response
 Increment in plasma amino acids, cholecystokinin and glucagon-like
peptide
Hall et al. (2003)
b-Lactoglobulin Transporter
 Retinol
 Palmitate
 Fatty acids
 Vitamin D and cholesterol
Puyol et al. (1991)
Wu et al. (1999)
Puyol et al. (1991)
Wang et al. (1997)
Enhancement of pregrastic esterase activity Perez et al. (1992)
Transfer of passive immunity Warme et al. (1974)
Regulation of mammary gland phosphorus metabolism Farrell et al. (1987)
a-Lactalbumin Prevention of cancer de Wit (1998)
Lactose synthesis Markus et al. (2002)
Treatment of chronic stress-induced disease Ganjam et al. (1997)
Bovine serum albumin Fatty acid binding Walzem, Dillard, and German (2002)
Anti-mutagenic function Bosselaers, Caessens, Van Boekel, and Alink (1994)
Prevention of cancer Laursen et al. (1990)
Immunomodulation
 Disease protection through passive immunity
Ormrod and Miller (1991)
Mitra et al. (1995), Tomita et al. (1995),
Loimaranta et al. (1999)
Immunomodulation Antibacterial activity
 HIV
Oona et al. (1997), Freedman et al. (1998)
Antifungal activity Okhuysen et al. (1998)
Opioid activity Sharpe et al. (1994)The actual concentrations of whey proteins depend on
the type of whey (acid or sweet), the source of milk (bovine,
caprine or ovine), the time of the year, the type of feed, the
stage of lactation and the quality of processing. Acid whey
– the pH of which is equal to or smaller than 5.1, is
obtained by direct acidiﬁcation of milk, as happens in cot-
tage cheese manufacture. Sweet whey – the pH of which is
equal to or higher than 5.6, is obtained after rennet-coagu-
lation, as happens in most cheese making processes world-
wide (Pintado, Macedo, & Malcata, 2001).In the latest two decades, the evolution of separation
technologies, viz. those relying on selective, porous mem-
branes, have permitted a number of protein whey compo-
nents to become widespread additives in food. Whey may
indeed be subject to several treatments, thus originating
whey products with speciﬁc qualitative and quantitative
proﬁles of proteins, minerals, lipids and sugars; the afore-
mentioned membrane-based separation technologies
include ultraﬁltration (UF) to concentrate proteins, or dia-
ﬁltration (DF) to remove most lactose, minerals and low
Whey protein concentrates and whey protein isolatesmolecular weight components – and thus produce whey
protein concentrates (WPC). Depending on their concen-
tration, there are WPC containing 35%, 50%, 65% and
80% (w/w) protein. When the threshold of 90% (w/w) pro-
tein is reached, a whey protein isolate (WPI) is accordingly
obtained – which is a protein concentrate bearing high-
quality and purity. Both those products are used as vectors
for the promotion of many biological properties upon
addition to foods. If a thermal process is applied to whey
then a-LA denatures easily, so it fraction can be separated
via precipitation (Huﬀman & Harper, 1999).The biological feature of whey proteins that has been
more thoroughly reviewed is their antimicrobial function
(Clare, Catignani, & Swaisgood, 2003). WPC enriched with
Helicobacter pylori-speciﬁc antibodies produced by lactat-
ing cows prevented infections thereby (Early, Hardy,
Forde, & Kane, 2001).
On the other hand, proteins chemically modiﬁed by 3-
hydroxyphthalic anhydride (3-HP), viz. BSA, a-LA and
b-LG, were tested for their antiviral action against such
enveloped viruses as human herpes simplex virus type 1
(HSV-1), bovine parainﬂuenza virus type 3 and porcine
respiratory corona virus (Oevermann, Engels, Thomas, &
Pellegrini, 2003). Of those three viruses, only HSV-1 was
sensitive to 3-HP-proteins. All said chemically modiﬁed
proteins exhibited antiviral activity against HSV-1 when
assayed before, during or after infection; however, signiﬁ-
cantly higher concentrations therof were required to pro-
duce HSV-1 inhibition if present before infection, than
during or afterwards.Whey proteins suppressed in vitro lymphocyte mitogen-
esis and alloantigen-induced proliferation, when included
in mature murine lymphocytes solutions (Barta, Barta,
Crisman, & Akers, 1991). Modiﬁed WPC can also suppress
the mitogen-stimulated secretion of c-interferon, as well as
the surface expression of interleukin-2 receptor, when
added to T and B lymphocyte cultures (Cross & Gill,
1999). On the other hand, Mercier, Gauthier, and Fliss
(2004) claimed that addition of whey proteins from micro-
ﬁltered-WPI to cell culture media, at a concentration of
100 lg/ml, stimulates in vitro proliferation of murine spleen
lymphocytes.
Gluthatione (GSH) is naturally found in all cells of
mammals, where it provides the main intracellular defense
against oxidative stresses – when illness occurs, GSH is
depleted because of said stress (Fig. 2). The amino acids
cysteine, glutamate and glycine are part of the primary
structure of this peptide; cysteine incorporation is the
rate-limiting step for its synthesis; and both cysteine and
glutamine are major players in the coordinated T-cell
response of macrophages and lymphocytes. Recall that
whey proteins are rich in cysteine and glutamate residues;
this suggests that their ingestion may contribute to increase
the level of free cysteine, and consequent production of
GSH. WPC is indeed an eﬀective cysteine donor for GSH
replenishment, during immune deﬁciency states; note that
GSH is important in immune regulation and cancer pre-
vention in animals, in improvement of immune and liver
functions, and in helping overcome GSH-deﬁciency in
seropositive and Alzheimer’s disease patients.
Cell culture studies and in vivo experiments (Gomez,
Ochoa, Herrera-Insua, Carlin, & Cleary, 2002) have dem-
onstrated that whey proteins may enhance non-speciﬁc
and speciﬁc immune responses. Dietary supplementationMammalian
cells
Whey
proteins Cysteine Glutathion
Fig. 2. Schematic diagram of glutathione (GHS) synthesis following whewith a whey-based product increased lymphocyte GSH lev-
els in patients suﬀering from lung inﬂammation associated
with cystic ﬁbrosis (Grey, Mohammed, Smountas, Bahlool,
& Lands, 2003).
The already mentioned high concentration of amino
acid precursors in the synthesis of GSH – i.e. cysteine
and glutamate in whey proteins, is believed to contribute
to said immuno-enhancing eﬀects (Wong & Watson, 1995).
Furthermore, the (long-term) Immunocal supplement
is a WPC that has proven eﬀective toward improvement
of liver disfunctions in patients exhibiting chronic hepatitis
B. Serum alanine aminotransferase (ALT) activity
decrease, and plasma GSH levels increased in most patients
suﬀering from that condition, 12 weeks after provision of
the aforementioned supplement started; on the other hand,
serum lipid peroxide levels decreased signiﬁcantly, and
interleukin (IL)-2 levels and natural killer (NK) activity
increased signiﬁcantly (Watanabe et al., 2000). WPC has
also been reported (Rosaneli, Bighetti, Anto´nio, Carvalho,
& Sgarbieri, 2002) to protect the gastric mucosa from eth-
anol damage; this protection depends on the sulfhydryl
compounds present therein. In addition, WPC in moderate
concentrations (10 mg/ml) can promote GSH production,
which in turn enhances the antioxidant activity in a pheo-
chromocytoma (PC12) cell line after acute ethanol expo-
sure (Tseng et al., 2006).
The above ﬁndings have provided a basis for prevention
(or treatment) of HIV-infected patients, which possess sys-
temic GSH deﬁciency – that permits multiplication of that
virus. Inclusion of whey protein formulae in their diet is
accordingly an eﬀective and well-tolerated route to increase
their GSH levels (Micke, Beeh, Schlaak, & Buhl, 2001;
Micke, Beeh, & Buhl, 2002). Moreover, whey proteins pos-
sess inhibitory activity against HIV-1 enzymes themselves –
which is then crucial in attemps to constrain the life cycles
of said virus (Ng, Lam, Au, Ye, & Wan, 2001).Whey proteins have been claimed by Tsuda et al. (2000)
to prevent cancer; examples include breast and intestinal
cancers in female rats, when included in their diet (MacIn-
tosh, Regester, le Leu, Royle, & Smithers, 1995; Badger,
Ronis, & Hakkak, 2001). The impact of whey proteins
upon cancer prevention has been thoroughly reviewed by
Gill and Cross (2000). The whole whey protein system
apparently protects against colon and mammary tumourse
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y protein intake, and most important functions associated therewith.
that had been chemically induced in vivo (Hakkak et al.,
2000; Rowlands, He, Hakkak, Ronis, & Badger, 2001).
In vivo experiments have also unfolded the anticarcino-
genic and anticancer activities ascertained to WPC, via
their eﬀect upon increase of GSH concentration in relevant
tissues; stimulation of immunity via the GSH pathway
actually originates anti-tumour eﬀects in low-volume
tumours (Bounous, 2000). On the other hand, published
evidence (Parodi, 1998) suggests that WPC can deplete
tumour cells which possess a concentration of GSH higher
than normal cells, and in addition render them more vul-
nerable to chemotherapy; Immunocal actually caused
depletion of GSH and inhibition of proliferation of human
breast cancer cells in in vitro assays, at concentrations that
induce GSH synthesis in normal human cells.
Hydrolysed WPI protected against oxidant-induced cell
death in a human prostate epithelial cell line (RWPE-1),
again because of the increment of GSH synthesis eﬀected
thereby (Kent, Harper, & Bomser, 2003). WPI may also
protect from cancer by acting as a coadjuvant of baicalein
– an anticancer drug; the cytotoxity of this molecule is
enhanced by inducing more apoptosis in the human hepa-
toma cell line Hep G2, which is in turn associated with
depletion of GSH (Tsai, Chang, Chen, & Lu, 2000).
Whey proteins apparently facilitate attainment of
favourable weight and composition. Whey proteins were
found (Hall, Millward, Long, & Morgan, 2003; Roberts,
McMcrory, & Saltzman, 2002) to be more eﬀective in sati-
ation than caseins, when both these proteins were studied
in terms of food intake – based on ratings of hunger and
fullness by selected subjects, and on postprandial metabo-
lite and gastrointestinal hormone responses. These results
imply post-absorptive increases in plasma amino acids,
and suggest that both plasma cholecystokinin (CCK) and
glucagon-like peptide (GLP-1) are potential mediators
towards increased satiety response to whey.
Furthermore, whey proteins lower plasma and liver cho-
lesterol, as well as plasma triacylglycerol levels in model
animals fed with cholesterol-containing diets (Beena & Pra-
sad, 1997; Zhang & Beynen, 1993).
Whey proteins contribute to improve muscle strength
and reduce the tendency for bone breaking; these features
are directly related to their amino acid proﬁles. In fact,
their overall amino acid composition is rather similar to
that of skeletal muscle; hence, whey protein may be a good
anabolic supplement. The advantages of whey proteins in
terms of muscle anabolism rely on their fast absorption,
coupled with the leucine abundance required to initiate
synthesis – as well as on their amino acid composition, that
provides substrates for protein synthesis (Ha & Zemel,
2003). In women infected with HIV, muscle strength wasimproved following a diet rich in whey proteins (Agin
et al., 2001).
The loss of bone mass during menopause is a well doc-
umented realisation; whey proteins may provide help
toward bone formation and activation of osteoblasts (bone
cells) – especially in what concerns proliferation and diﬀer-
entiation of osteoblastic MC3T3-E1 cells (Takada, Aoe, &
Kumegawa, 1996). Bone metabolism is promoted by incre-
ments in the amount of such bone protein as collagen. Rats
fed with either plain whey protein or fractioned whey pro-
tein showed a signiﬁcant increase in resistance to bone
breaking, and in the amounts of hydroxyproline and pro-
line (i.e. structural amino acids of collagen) in the femur
(Takada et al., 1997). Recently, acidic protein fraction pre-
pared from mineral acid WPC reduced bone loss due to
ovariectomy, maintaining bone density above ovariectomy
levels at week 16 of feeding of mature female rats (Kruger
et al., 2006).
b-Lactoglobulin
b-LG is quantitatively the dominant whey protein (58%
(w/w)), and was ﬁrst discovered in 1934. When in isolated
form, it exhibits a low solubility (despite its globular nat-
ure) and a low ionic strength. Synthesized in the mammary
gland of ruminants (and other species) and designed to be
included in milk, this protein has several genetic variants –
of which b-LG A is the most common. It is composed
mainly of b-sheet motifs, and consists of 162 amino acid
residues – which lead to a molecular weight of ca.
18,277 kDa (Eigel et al., 1984). Its quaternary structure
depends on the medium pH: it occurs mainly as a stable
dimmer, with a molecular weight of 36,700 kDa, at pH val-
ues between 7 and 5.2; as an octamer, with a molecular
weight of ca. 140,000 kDa, at pH values between 5.2 and
3.5; and as a monomer, with two-cysteine residues per
monomer, at pH 3.0 and above 8.0 (de Wit, 1989).
b-LG plays a role in transfer of passive immunity to the
newborn, and in regulation of phosphorus metabolism at
the mammary gland (Farrell, Bede, & Enyeart, 1987).
The amino acid content of this protein is rather impor-
tant, because – besides fueling muscle growth, it is a source
rich in the essential amino acid cysteine, which is important
for synthesis of GSH (de Wit, 1998).
The actual biological function of b-LG is still unclear;
however it often binds to small hydrophobic ligands, such
as retinol, fatty acids, protoporphyrin IX, triacylglycerols,
alkanes, aliphatic ketones, aromatic compounds, vitamin
D, cholesterol, palmitic acid and calcium (at pH 5.0)
(Brown, 1984; Cho, Batt, & Sawyer, 1994; Farrell et al.,
1987; Futterman & Heller, 1972; O’Neil & Kinsella, 1987;
Patocka & Jelen, 1991; Puyol, Pe´rez, Ena, & Calvo, 1991;
Said, Ong, & Shingleton, 1989; Smith, Fantozzi, & Crevel-
ing, 1983; Wang, Allen, & Swaisgood, 1997; Wu, Pe´rez,
Puyol, & Sawyer, 1999). Speciﬁcally, this protein binds to
free fatty acids as they are released by pregastric lipases,
in order to facilitate digestion of milk fat (Perez & Calvo,
1995). Because of its high stability at low pH, b-LG pro-
tects hydrophobic molecules during passage through the
stomach, in order to deliver such ligands to a speciﬁc recep-
tor located in the intestine of the suckling neonate (Cho
et al., 1994).
a-Lactalbumin
a-LA is quantitatively the second most important pro-
tein in whey – representing ca. 20% (w/w) of the total whey
protein inventory, and is fully synthesized in the mammary
gland. Here a-LA acts as coenzyme for biosynthesis of lac-
tose – an important source of energy for the newborn (de
Wit, 1998). It contains 123 amino acid residues (its
sequence is quite homologous to that of lysozyme), which
lead to a molecular weight of 14,175 kDa (Brew, Castelli-
no, Vanaman, & Hill, 1970). Three genetic variants have
already been identiﬁed – A, B and C (Fox, 1989). Its glob-
ular structure is stabilized by four disulphide bonds, at pH
values in the range 5.4–9.0 (Evans, 1982).
a-LA contributes to reduce the risk of incidence of some
cancers – as it constrains cell division, when incubated in
distinct mammalian intestinal cell lines (Ganjam, Thorn-
ton, Marshall, & MacDonald, 1997). It can also be a
potent Ca2+-elevating and apoptosis-inducing agent
(Hakansson, Zhivotovski, Orrenius, Sabharwal, & Svan-
borg, 1995).
This protein also was demonstrated to possess anti-
proliferative eﬀects in colon adenocarcinoma cell lines
(Caco-2 or HT-29 monolayers), delaying initiation of cell
aptoesis, after 4 days of growth with low concentrations
(10–25 lg/ml) of such protein (Sternhagen & Allen, 2001).
This whey protein has been associated to treatment of
chronic stress-induced cognitive decline. In fact, an imbal-
ance in brain serotonin (5-hydroxytryptamine) function
was claimed to be a factor mediating the negative eﬀect
of chronic stress on cognitive performance; serotonin
release decreases under exposure to chronic stress, thus
decreasing the available concentrations of brain serotonin
and tryptophan (a precursor of serotonin) both of which
cause serotonin activity to fall below functional needs.
Due to its high tryptophan content (ca. 6% (w/w)), a diet
based on a-LA increases the plasma tryptophan-large neu-
tral amino acids (Trp-LNAA) ratio (Markus, Olivier, & de
Haan, 2002).BSA is not synthesized in the mammary gland, but
appears instead in milk following passive leakage from
the blood stream. It contains 582 amino acid residues,
which lead to a molecular weight of 66,267 kDa; it also
possesses 17 intermolecular disulphide bridges and one
thiol group at residue 34 (Fox, 1989). Because of its size
and higher levels of structure, BSA can bind to free fatty
acids and other lipids, as well as ﬂavour compounds (Kin-
sella, Whitehead, Brady, & Bringe, 1989) – a feature that is
severely hampered upon denaturation. Its heat-induced
gelation at pH 6.5 is initiated by an intermolecular thiol–
disulphide interchange, similar to what happens with b-
LG (de Wit, 1989).
One important property that has been associated to
BSA is the ability to inhibit tumour growth; in vitro incuba-
tion with human breast cancer cell line MCF-7 has pro-
vided adequate evidence thereof, which lies on
modulation of activities of the autocrine growth regulatory
factors (Laursen, Briand, & Lykkesfeldt, 1990).
The aforementioned binding properties of BSA depend
on the fatty acid (or other small molecules) in stake (Brown
& Shockley, 1982). Binding to fatty acids, that are stored in
the human body as fat, allow it to participate in synthesis
of lipids – which are a part of all outer and inner cell mem-
branes, and which provide energy; this issue has been
reviewed at some length by Choi et al. (2002).
The antioxidant activities of this protein have been tack-
led by Tong, Sasaki, McClements, and Decker (2000). BSA
has been shown to in vitro protect lipids against phenolic-
induced oxidation (Smith, Halliwell, & Aruoma, 1992).
IG constitute a complex group, the elements of which
are produced by B-lymphocytes; they make a signiﬁcant
contribution to the whey protein content – besides exerting
an important immunological function (especially in colos-
trums). These proteins are present in the serum and physi-
ological ﬂuids of all mammals; some of them attach to
surfaces, where they behave as receptors, whereas others
function as antibodies, which are released in the blood
and lymph. IG are subject to postnatal transfer via colos-
trum – as the placenta does not permit passage of macro-
molecules (Butler, 1994). The structure and general
function of bovine IG have been reviewed by Korhonen,
Marnila, and Gill (2000).
In terms of quaternary structure, IG are either mono-
mers or polymers of a four-chain molecule, consisting of
two light polypeptide chains (with a molecular weight in
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the range 25,000 kDa) and two heavy chains (with molecu-
lar weight of 50,000–70,000 kDa) (Mulvihill & Donovan,
1987). The nomenclature of the elements of this family is
based on their immunological cross-reaction with reference
proteins, preferably of human origin, as proposed by WHO
(Butler, 1971). There are, however, three basic classes of
IG: IGG, IGA and IGM, although IGG is often sub-divided
into two subclasses – IGG1 and IGG2. Up to 80% (w/w) of
all IG in milk or whey is accounted for by IGG (de Wit,
1989) but qualitatively, the family of IG found in bovine
whey and colostrum include IGA and secretory IGA,
IGG1, IGG2 and IGG fragments, IGM, IGE, J-chain or com-
ponent, and free secretor component.
Antibody concentrates derived from immune colostrum
and milk collected from cows immunised with inactivated
human rotavirus (HRV) serotypes 1 (Wa) and 2 (S2), as
well as simian rotavirus serotype 3 (SA11) were shown to
possess preventive (or treatment) features in enteric disease
caused by said viruses in piglets (Schaller et al., 1992), and
in therapeutics of child infections caused thereby (Sarker
et al., 1998). Infant gastritis originated by H. pylori is well
fought via a diet including immune milk containing speciﬁc
anti-H. pylori antibodies (Oona et al., 1997). Other studies
were performed against infections in calves caused by
enterotoxigenic Escherichia coli (Moon & Bunn, 1993),
and even infections in humans caused by enteropathogenic
(Freedman, Tacket, & Delehanty, 1998).
Okhuysen et al. (1998) tackled the use of immune bovine
colostrum on treatment of HIV-patients bearing infections
caused by Cryptosporidium parvum. There is also evidence
of protection via bovine antibodies against dental caries
caused by cariogenic streptococci (Loimaranta et al.,
1999). In a study involving two groups of mice – one fed
with immune milk obtained from cows immunised with a
mixed bacterial ﬂora, and a control group fed regularly,
they were exposed to lethal doses of irradiation, and their
survival rate was compared; the survival rate of the test
group was higher than that of the control group, and the
concentration of IGA in cell culture derived from Peyer’s
patches, mesenteric lymph node and spleen of the former
group was also higher (Kobayashi et al., 1991).
IG are recognised to provide protection against diseases
in the newborn through passive immunity. Most studies
have focussed on newborn ruminants, but more recent
research has started exploring the eﬀects on non-ruminants
and adults.
Feeding of pregnant cows with immune milk, or sys-
temic immunisation thereof has been a common technique
applied in several research eﬀorts; the latter procedure
increases the levels of antibodies against immunising bacte-
ria, and also reduces susceptibility to disease (Ormrod &Miller, 1991). Vaccination of pregnant cows originates
colostrum characterized by high concentrations of speciﬁc
antibodies against the antigens of the vaccine used (Korho-
nen et al., 1995). Tomita, Todhunter, Hogan, and Smith
(1995) studied the eﬀect on cows of a vaccine containing
a lipopolysaccharide–protein conjugate derived from
E. coli J5; immunisation enhanced the serum antibody titer
to J5, but not the whey titer to IGG.
Immune milk was also suggested to lower blood pres-
sure (Sharpe, Gamble, & Sharpe, 1994). In a double-blind,
clinical-trial study, the eﬀects on reduction of plasma cho-
lesterol and blood pressure of immune milk produced by
dairy cows previously hyper-immunised with a multivalent
bacterial vaccine were assessed, involving human hyper-
cholesterolemic subjects – who consumed 90 g of immune
milk daily, versus regular milk; the former was a useful
adjunct in the dietary management of hypercholesterolemia
(Sharpe et al., 1994).
BLF is an iron-chelating, monomeric glycoprotein,
characterized by a molecular weight of 80,000 kDa, to
which two carbohydrate groups are attached (de Wit,
1989; Lonnerdal & Iyer, 1995). It is present in the human
body as a secretor protein – synthesized by glandular epi-
thelial cells and mature neutrophils, and can be found in
milk, saliva, tears, nasal and intestinal secretions, pancre-
atic juice and seminal ﬂuid, as well as in secondary granules
of neutrophils (Lonnerdal & Iyer, 1995). Bovine milk con-
tains between 0.02 and 0.35 mg/ml of BLF, depending on
the period of lactation – whereas human milk contains
ca. 4.00 mg/ml. Two other proteins with iron-chelating
properties are transferrin and ovotransferrin; these proteins
– as happens with BLF, possess two metal-binding sites,
designed to attach to ferric ion (Fe3+) and bicarbonate
ion ðHCO3 Þ, respectively. The iron-free protein is usually
termed apo-BLF.
A review on the antimicrobial properties of lactoferrin is
available elsewhere (Fernaud & Evans, 2003). Its antibacte-
rial activity has been attributed to the aforementioned
iron-binding property – which makes it unavailable the
(otherwise active) microorganisms, or by direct binding
to their microbial membrane. Nevertheless, the action of
this protein is not restricted to bacteria with iron require-
ments (e.g. coliforms), because apo-BLF was also shown
to possess bactericidal power against a wide range of
microorganisms (Dionysius, Grieve, & Milne, 1993). BLF
can damage the outer membrane of Gram-negative bacte-
ria via binding to Lipid A lipopolysaccharides (LPS) –
which compose their asymmetric lipid bilayer membrane
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(Appelmelk et al., 1994); release thereof causes structural
changes, which include loss of membrane potential and
integrity. The antibacterial activity of LF also depends
on its concentration or the degree of iron saturation of
the molecule, and on its interaction with mineral medium
constituents (Payne, Davidson, Oliver, & Christen, 1990).
The antimicrobial eﬀect of BLF can be taken advantage
of in treatment of enteric infections (as depicted in Table 3).Table 3
Antiviral and antimicrobial properties of whey proteins, and mechanisms of a
Protein Protection against Protection mecha
Immunoglobulin
(antibodies)
Helicobacter pylori Agglutination
Enteropathogenic Escherichia coli Bacteriolysis
Cariogenic streptococci Bacteriostasis
E. coli J5 Opsonization
Cryptosporidium parvum
Human and simian rotavirus Neutralization of
Lactoferrin Enterotoxigenic E. coli (ETEC) Binding of iron
Enterohemorragic E. coli (EHEC) Destabilization o
Shigella ﬂexneri-induced
inﬂamatory enteritis
Synergetic action
lysozyme or antib
Haemophilus inﬂuenzae Modulation of m
cell functions or
Vibrio cholerae Blood neutrophil
leucocytes
Streptococcus mutans
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combination with penicillin G, BLF enhances Staphylococ-
cus aureus susceptibility to immune-defense mechanisms;
this can be a beneﬁcial trait in the treatment of infections
caused thereby (Diarra et al., 2003). Another bacterium
inhibited by that protein is Streptococcus mutans – the
prime cause of dental caries; BLF inhibits aggregation of
those saliva induced-bacteria to salivary components, or
to salivary ﬁlms (Mitoma, Oho, Shimazaki, & Koga,
2001; Oho, Mitoma, & Koga, 2002). In addition, BLF has
been demonstrated (Hoerr & Bostwick, 2000) to protect
against such pathogens as Haemophilus inﬂuenzae, which
causes otitis media (ear infections) in children. In vivo and
in vitro tests carried out by Dial et al. (1998) conﬁrmed that
BLF possesses antimicrobial activity againstH. pylori infec-
tions at pH 6, at concentrations above 0.5 mg/ml, and is
able to clear H. felis infection in mouse; and that a non-
iron-dependent component of such a protein displays anti-
microbial activity. Thereof, use of bovine BLF as therapeu-
tic agent to assist antimicrobial agents towards erradication
of such harmful bacterium was suggested (Di Ma´rio et al.,
2003). Recently, BLF was found to exibit antibacterial
activity against Carnobacterium viridans, at neutral pH
and refrigeration temperatures (al-Nabulsi & Holley, 2005).
Recent studies encompassing guinea pigs have demon-
strated that iron-unsaturated BLF is active against the
fungi Trichophyton mentagrophytes and Trichophyton
rubrum – which are responsible for dermatophytosis
(Wakabayashi et al., 2000; Wakabayashi et al., 2002). Diets
containing BLF fed to guinea-pigs previously infected (or
immunised) with T. mentagrophytes potentiated the host
antifungal defense systems, by modulating the mononu-
clear cell functions encompassing antifungal activity, or
the release of peripheral blood neutrophil polymorphonu-
clear leucocytes in plasma.
Incidentally, BLF was the ﬁrst whey protein which was
ascribed an anti-viral activity; this subject was comprehen-
sively reviewed by van der Strate, Beljaars, Molema,
Harmsen, and Meijer (2001). Said activity was suggested
against several species of virus, as depicted in Table 3.
BLF also plays a preventive role of AIDS-like disease
(ALD) in mice, at least for a restricted period of time –
when administrated 20 days prior to viral infection (Luba-
shevsky et al., 2004).
The major mechanisms by which BLF is believed to
exert its antiviral activity are summarized in Table 3.
BLF interacts with viruses, but not with cells infected
thereby; however, it can interact with the host cells before
they are infected – like happens with hepatitis B virus
(HBV) for which interaction with the cell surface proteins
blocks viral adhesion to the cells themselves (Hara et al.,
2002). This issue was conﬁrmed with regard to E1 and
E2 HVC envelope proteins in vitro (Yi, Kaneko, Yu, &
Murakumi, 1997), and in the case of HIV-1 reverse trans-
criptase (Ng et al., 2001). In what concerns hepatitis C
and G viruses (HVC and HGV, respectively), BLF inhibits
the viral entry into hepatocyte and lymphocyte cells – via
neutralising the virion, and blocking the invasion of the cellthereby (Ikeda et al., 1998). In the case of HIV-1, succiny-
lation of that protein slightly increases the extent of inhibi-
tion of the HIV-1 reverse transcriptase (Wang, Ye, & Ng,
2000). In vivo experiments involving HIV-infected individ-
uals have indicated that BLF inhibits strongly that enzyme,
but only slightly protease and integrase (Ng et al., 2001).
Recently, LF was found to inhibit in vitro enterovirus 71
(EV 71), via binding to one of their four capsid proteins,
VP1; furthermore, BLF can induce IFN-a expression of
neuronal (SK-N-SH) cells and inhibit EV 7-induced IL-6
production (Weng et al., 2005).
Except in the case of simian rotavirus (Superti & Donel-
li, 1995), another mechanism hypothesized for binding of
BLF to host cells is via a receptor (or co-receptor) – such
as heparin sulphate proteoglycans (HSPG), which prevent
binding of the virus thereto, and subsequent infection of
the host cell (Laquerre et al., 1998). Recently, Marchetti,
Trybala, Superti, Johansson, and Bergstro¨m (2004) eluci-
dated the mechanism of BLF antiviral activity against
HSV-1 infection initiates infection of cells via binding to
it glycosaminoglycans (GAG) (WuDunn & Spear, 1989),
which are composed of repeating (speciﬁcally sulphated)
disaccharide units. BLF binds speciﬁcally to the two com-
mon classes, heparan sulfate (HS) and/or chondroitin sul-
fate (CS), on cell surfaces – hence occupying moieties
that would function as initial receptors for said virus. This
mechanism was promote (Drobni, Na¨slund, & Evander,
2004) to be similar to human papillomavirus inhibition.
Bovine BLF was also shown (Ishii et al., 2003) to reduce
serum HVC-RNA levels in patients suﬀering from chronic
hepatitis C; a dominant environment of Th1-cytokine is
produced in the peripheral blood that favours eradication
of HVC via interferon (IFN) therapy.
BLF plays an important role upon stimulation of the
immune system, probably owing to increase of macrophage
activity, as well as induction of inﬂammatory cytokines,
including IL-8, TNF-a and nitric oxide (McCormick, Mar-
key, Morris, Auld, & Alexander, 1991; Sorimachi, Akimot-
o, Hattori, Ieiri, & Niwa, 1997), stimulation of
proliferation of lymphocytes (Potjewijd, 1999), and activa-
tion of monocytes, natural killer (NK) cells (Ambruso &
Johnson, 1981; Nishiya & Horwitz, 1982) and neutrophils
(Gahr, Speer, Damerau, & Sawatzki, 1991). Kuhara et al.
(2000) administrated LF orally, and reported that the
induction of IL-8 secretion by epithelial cells acts so as to
enhance Th1 cell functions, and augment NK cells and
cytotoxic lymphocyte activities.
BLF has also been reported to stimulate humoral
immune response to sheep red blood cells, to promote
appropriate intestinal and peripheral speciﬁc antibody
response, and to modulate production of lymphokines
(German, Dillard, & Walzem, 2000). When of bovine ori-
gin, both BLF and hydrolysed forms thereof enhance
mucosal immunity – which is dependent on the ability of
BLF to bind to the intestinal mucosa (Debbabi, Dubarry,
Rautureau, & Tome, 1998).
The aforementioned activities depend on the target cells,
and arise from the ability of BLF to bind to speciﬁc mole-
cules. As suggested before, BLF possesses an LPS-binding
property, and this property is a part of the immunomodu-
latory function of BLF. LPS, as a highly cationic glycopro-
tein, binds to lipid A portion of LPS via charge–charge
interaction. Recently, Na et al. (2004) claimed that, upon
mixing LPS and puriﬁed LF, they subsequently formed a
complex LPS-LF, which induced inﬂammatory mediators
in macrophages rather than LPS activity. The latter work
proposed that lipid A – a toxic portion of LPS, can be rec-
ognized even after LF-LPS has been formed, and that this
complex induces tolerance to LPS-stimulation.
Several studies, based on data from such animals as
mice and rats, have provided stronger and stronger evi-
dence for the therapeutic value of BLF in treating distinct
types of cancer (Gill & Cross, 2000), viz. colon cancer
(Masuda et al., 2000). The iron-binding capacity of BLF
has been put forward as the molecular rationale behind
such a biological activity; free iron may act as a mutagenic
promoter, by inducing oxidative damage to the nucleic acid
structure; hence, when BLF binds iron in tissues, it reduces
the risk of oxidant-induced carcinomas (Weinberg, 1996)
and colon adenocarcinomas (Tsuda et al., 1998). Studies
are available (Masuda et al., 2000; Tanaka et al., 2000) that
pertain to such other cancers as lung, bladder, tongue and
oesophagus, and which convey similar results.
Supplementing the diet of dairy calves with BLF has
been tried, along with monitoring its eﬀect on their perfor-
mance (Joslin et al., 2002); BLF was able to improve the
average daily gain, and decrease weaning in dairy calves.
An in vivo research eﬀort conducted by Kajikawa et al.
(1994) led them to hypothetize that BLF may act as an
antiatherogenic agent, by inhibiting accumulation of cho-
lesterol esters in macrophages – which are ‘precursors of
the foam cells found in early atherosclerotic lesions. This
protein can furthermore survive gastric digestion in adults
(Troost, Steijns, Saris, & Brummer, 2001), and bears no
toxicity when orally administered to rats (Yamauchi
et al., 2000); these two reasons account for its regular use
as bioactive ingredient for therapeutic administration.
Lactoperoxidase (LP) is present in a variety of animal
secretions, viz. tears, saliva and milk. A member of the
family of mammalian peroxidases, it is one of the most
abundant enzymes in plain milk – it represents ca. 1%
(w/w) of the total protein pool in whey (Reiter & Perrau-
      Lactoperoxidasedin, 1991). The complete LP system (i.e. enzyme plus sub-
strate) was originally characterized in milk by Reiter,
Pickering, Oram, and Pope (1963); its activity depends on
many factors, e.g. animal species (Pruitt & Reiter, 1985),
breed and lactation cycle (Zapico, Gaya, de Paz, Nunez,
& Medina, 1991).
Other members of that group of oxidoreductases include
myeloperoxidase (present in neutrophils and monocytes),
eosinophil peroxidase and thyroid peroxidase. Chemical
sequencing unfolded a great degree of homology between
them, which suggests a close evolutionary relationship
among those enzymes (Petrides, 1998). Peroxidases utilise
hydrogen peroxide to oxidise thiocyanate to hypothiocya-
nate, and are active in a variety of anatomic locations
(Thomas, Bozeman, & Learn, 1991).
LP is an important part of the natural host defense sys-
tem in mammals, which provides protection against invad-
ing microorganisms (de Wit & van Hooydonk, 1996). The
antibacterial ability of peroxidases was ﬁrst described
(Agner, 1941) in verdoperoxidase (later renamed myeloper-
oxidase) from leukocytes – which is able to inactivate diph-
theria toxin; such an antimicrobial activity has been proven
against Gram-positive (Zapico, Gaya, Nunez, & Medina,
1995) and negative (Zapico et al., 1995) microorganisms.
The mechanism of action of LP has been explained in
detail elsewhere (de Wit & van Hooydonk, 1996); such an
enzyme is more active at acidic pH (Wever, Kast, Kasino-
edin, & Boelend, 1982). The antimicrobial activity of per-
oxidases depends on the ion acting as electron donor.
The LP system is completed when LP, thiocyanate ion
(SCN) and hydrogen peroxide (H2O2) are present
together (Reiter & Harnulv, 1984). The thiocyanate anion
– which is necessary for the antibacterial activity of LP
be expressed, appears to signiﬁcant extents in saliva, milk
and airway secretions (Reiter & Perraudin, 1991), and orig-
inates from glucosinolates via detoxiﬁcation of the cyano-
genic glucosides present in the feed. The amount of
SCN in cow’s milk ranges from 0.1 to 15 mg/kg (Perrau-
din, 1991); its concentration varies according to animal
species (de Wit & van Hooydonk, 1996), breed, lactation
cycle (Zapico et al., 1991), season (Dabur, Srivastava, &
Kapoor, 1996) and composition of feed (Thomas, 1981).
LP-catalysed reactions yield short-life, intermediary oxi-
dation products of SCN, which are responsible for its
antibacterial activity. The major intermediary oxidation
product, at physiological pH, is hypothiocyanate
(OSCN), which is produced at the stoichiometric ratio
of 1 mol/mol of hydrogen peroxide (Pruitt & Tenovuo,
1982). Other products possessing antimicrobial activity
are also formed in this reaction, viz. cyanosulphurous acid
(HO2SCN) and cyanosulphuric acid (HO3SCN) (Bjorck,
1979); these compounds are able to oxidise sulphidrile
groups of bacterial proteins (Reiter & Harnulv, 1984).
The anion OSCN is thought to mediate bacterial killing,
as it is cell-permeable and can inhibit glycolysis, as well as
nicotinamide adenine dinucleotide (NADH)/nicotinamide
adenine dinucleotide phosphate (NADPH)-dependent
reactions in bacteria (Reiter & Perraudin, 1991).
Hydrogen peroxide is produced in endogenous form by
polymorphonuclear leukocytes (de Wit & van Hooydonk,
1996), and by numerous other microorganisms (Pruitt,
Kamau, Miller, Mansson-Rahemtulla, & Rahemtulla,
1990), viz. resident bacteria in such sites as the oral cavity,
or generated in situ by cells the respiratory tract (Reiter &
Perraudin, 1991). It can also be produced by speciﬁc gener-
ator systems, such as via oxidation of ascorbic acid, oxida-
tion of glucose-oxidase, oxidation of hypoxanthine by
xanthine oxidase, and manganese-dependent aerobic oxi-
dation of reduced pyridine nucleotides by peroxidase
(Wolason & Sumner, 1993). The H2O2 content is rapidly
reduced by catalases and peroxidases that are adventitious
in milk; hence, it is normally present to very small levels
(Bjorck, Rosen, Marshall, & Reiter, 1975). While H2O2
can behave as bactericidal or bacteriostatic, experimental
evidence indicates that inhibition of bacterial growth is
far more eﬃcient in the presence of the complete LP system
(Reiter & Perraudin, 1991).
Studies pertaining to the antimicrobial eﬀects of LP
have focused on its role upon thermal resistance of Salmo-
nella spp. (Doyle & Mazzotta, 2000), in both raw (Heuve-
link et al., 1998) and mature milk (Shin, Tomita, &
Lonnerdal, 2000). Peroxidases are important in inhibiting
dental caries, in controlling microorganism growth in milk
from lactating animals, and in cell-mediated pathogen kill-
ing (Reiter & Perraudin, 1991). Poulsson, Hegg, and Cast-
berg (1986) patented a process that uses an LP system for
dental (and other wound) treatment.
Bacterial resistance to LP-mediated killing may occur
via enzymes which act in a reverse way – and which inacti-
vate OSCN, prevent pigment generation and constrain
anaerobic metabolism (Reiter & Perraudin, 1991).
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